PRNewsWire
25 Mar 2026, 13:00 UTC · 33w ago
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Impact · against what's priced in
Ultragenyx (RARE) faces a severe valuation hit following the failure of two Phase III trials for setrusumab and a subsequent class action lawsuit. While the price has already dropped 42%, the ongoing litigation adds further financial and reputational risk.
- RARE−0.90
No priced-in read yet





